Insertional mutagens such as viruses and transposons are a useful tool for performing forward genetic screens in mice to discover cancer genes. These screens are most effective when performed using hundreds of mice; however, until recently, the cost-effective isolation and sequencing of insertion sites has been a major limitation to performing screens on this scale. Here we present a method for the high-throughput isolation of insertion sites using a highly efficient splinkerette-PCR method coupled with capillary or 454 sequencing. This protocol includes a description of the procedure for DNA isolation, DNA digestion, linker or splinkerette ligation, primary and secondary PCR amplification, and sequencing. This method, which takes about 1 week to perform, has allowed us to isolate hundreds of thousands of insertion sites from mouse tumors and, unlike other methods, has been specifically optimized for the murine leukemia virus (MuLV), and can easily be performed in a 96-well plate format for the efficient multiplex isolation of insertion sites.
INTRODUCTION

Insertional mutagenesis in mice
Human tumors arise as a result of the sequential acquisition of mutations, which may include point mutations, changes in DNA copy number, translocations and epigenetic changes in the genome. Not all of these alterations are causally implicated in oncogenesis, and separating the 'driver' mutations from the 'passenger' mutations 1 is not possible without functional validation in vitro or preferably in vivo. Insertional mutagenesis in the mouse using either viruses or transposons makes it possible to perform genomewide screens for genes that cooperate in cancer formation. Once integrated in the genome, the pro-virus or transposon acts as a 'tag' allowing its location to be determined and effects on gene function assessed. Therefore, insertional mutagenesis studies in the mouse are a useful complement to the analysis of human cancer genomes, and facilitate the identification of 'driver' cancer genes.
In the past, insertional-mutagenesis screens in mice have been performed using slow-transforming retroviruses. These viruses include murine leukemia viruses (MuLV) and mouse mammary transforming viruses (MMTV), which generate tumors of the lymphoid system and mammary gland, respectively 2 . More recently, transposon-based methods, such as those that use the Sleeping Beauty transposon 3 , have been developed to carry out mutagenesis in other tissues, including the liver 4 , the brain 5 and soft-tissue compartments 6, 7 . Although conceptually straightforward, isolating and sequencing insertion sites (either viral or transposon-mediated) from hundreds or thousands of tumors can be cumbersome and expensive. Hence, methods that allow insertion sites to be efficiently amplified and sequenced are critical for the success of these screens.
Strategies for isolating insertion sites
To isolate insertion sites, it was once necessary to generate genomic libraries of each tumor and to screen these by colony lifting using viral long-terminal repeat (LTR) sequences as probes 8 . Recently a variety of approaches have been developed for insertion-site isolation, including inverse-PCR 9 , vectorette 10 or splinkerette-PCR 11 , panhandle-PCR, Alu-PCR, capture-PCR and boomerang DNA amplification 12 . Although inverse-PCR has been a widely used approach for isolating insertion sites, it is relatively inefficient when compared with other PCR-based approaches 12 . Approaches such as panhandle-PCR, Alu-PCR, capture-PCR and boomerang DNA amplification have not been widely used because they can be problematic to optimize and do not readily lend themselves to scaling-up for high-throughput applications. Vectorette-PCR can be highly sensitive, but is prone to the amplification of contaminants by 'end-repair priming' 10 . End-repair priming involves the free cohesive ends of unligated vectorettes and inserts, which are based on restriction sites that produce 5¢ overhangs. During the first cycle of PCR these ends are 'filled in' , and after the subsequent denaturing step these ends are able to anneal to each other and to initiate priming. Extension across a vectorette sequence at either end of the insert molecule will result in the production of a sequence complementary to the vectorette primer. When this happens exponential PCR amplification may occur without the involvement of the specific target-DNA primer, and the pool of PCR products in the reaction will become swamped by this contaminant, which is usually preferentially amplified. In contrast splinkerette-PCR 11, 13 , which is a variant of ligationmediated PCR, was developed to overcome the problem of 'end-repair priming' by using a splinkerette 'hairpin loop' (Fig.  1a,b) . Although not perfect, because like any PCR-based method the splinkerette-PCR is potentially prone to PCR amplification bias and contamination, it has become the most widely accepted technique for the amplification of viral and transposon insertion sites.
The principle of splinkerette-PCR Splinkerette-PCR was originally developed to enable the PCR amplification of sequences that lie between a known DNA sequence 11 , such as a viral LTR or transposon IR/DR, and a nearby restriction site. Unlike vectorettes, which contain a central DNA mismatch within them, splinkerette adaptors incorporate a hairpin structure (Fig. 1b) . Annealing of oligonucleotides to create the splinkerette adaptor creates an overhang compatible with overhangs generated by the restriction of the (genomic) DNA with the restriction enzyme of choice. However, as the oligonucleotides used to create the splinkerette adaptor are not phosphorylated at their 5¢ terminus, they should only undergo single-stranded ligation at the 5¢ end of the template sequences. To amplify the DNA, a primer that can only bind to the newly synthesized strand of the splinkerette adaptor is used in the PCR reaction. This ensures that the DNA cannot be amplified until synthesis from a primer that binds to the target sequence, e.g. the viral LTR, has been achieved. This feature improves specific amplification of splinkerette-adapted sequences. Furthermore, during the elongation step of the PCR reaction the free 3¢ end of the splinkerette will 'flip back' on itself to form a stable double-stranded DNA hairpin, which is unable to participate in end-repair priming. An additional factor that increases the specificity of the splinkerette reaction is that only one strand is available for non-specific priming, unlike vectorettes, where mispriming can occur from both strands. Some splinkerette protocols have also been adapted to incorporate a C3 spacer 'blocking group' at the 3¢ end of the splinkerette oligonucleotides, which can also help to prevent mis-priming 6, 7, 11 . Collectively, these features make splinkerette-PCR efficient, accurate and highly sensitive.
Sequence analysis of splinkerette-insertion sites Tumors generated using either transposons or retroviruses are mostly oligoclonal. In addition, cells within each tumor contain multiple insertion events, making the amplification of insertion sites from a tumor a multiplex reaction. For sequence analysis it is necessary to de-multiplex each splinkerette-PCR, so that the sequence of individual insertion sites can be retrieved.
There are several approaches that can be used for de-multiplexing. The first is shotgun cloning of individual splinkerette-PCR products followed by capillary read sequencing, and the second is barcode splinkerette-PCR followed by 454 parallel sequencing. The major advantage of shotgun cloning followed by capillary read sequencing is that it is extremely robust. We have developed an approach called TOPO-shotgun (Fig. 2) , which we have used to generate the DNA sequence of over 100,000 insertion sites from over 1,000 splinkerette-PCR reactions generated from both retroviral 14 and transposon-induced tumors. The other advantage of TOPO-shotgun is that the sequences generated from capillary reads are long, up to 1 kb, hence it is possible to obtain the sequence from the viral LTR or transposon IR/DR, the sequence of the junction between the insertional mutagen and the genome, a length of genomic sequence and also to read sequence into the splinkerette adaptor. This facilitates the removal of contaminated splinkerette-PCR products and the accurate alignment and orientation of insertion sites on the genome. The major disadvantage of TOPO-shotgun cloning is that it is expensive and requires considerable infrastructure for colony picking, prepping and sequencing. However, it is still the method of choice for the analysis of small numbers of tumor samples (o20), where the use of parallel sequencing is unnecessary and uneconomical.
The alternative approach for obtaining the sequence of insertion sites is to employ 454 parallel sequencing of pools of barcoded splinkerette-PCR reactions from multiple independent tumors (Fig. 2) . As 454 employs single-molecule sequencing technology, pools of PCR products can be effectively de-multiplexed on the machine. By incorporating 'barcode' sequences (short DNAsequence identifiers) in the splinkerette-PCR primers, it is possible to pool together splinkerette products from multiple tumors and to use the barcode as a tag to determine which sequence belongs to each tumor within the pool. The 454 sequencing platform is a very efficient way of analyzing insertion sites. A single 454 run can be carried out in 1 day, yielding over 400 Mb of sequence 15 . Importantly, it is possible to run up to eight independent samples or pools of samples, on each flow cell. DNA sequence reads on the Roche 454 Gs20 machine are short, B100 bp, whereas the sequences generated by the 454 FLX are on average 250 bp in length. For most insertion sites the length of DNA sequence generated on the FLX is sufficient to identify the IR/DR or LTR, the junction between the IR/DR or LTR and the genome, and in many cases to generate sequence into the splinkerette adaptor. Although this is the first working protocol describing the use of splinkerette-PCR and 454 for insertion-site isolation from MuLV-induced tumors 14 , similar methods exist for HIV and other viruses 16 .
Experimental design
In this protocol we have focused on the isolation of insertion sites from MuLV-induced mouse lymphomas, but with adaptation of the primer sequences, this protocol is applicable to the isolation of insertion sites generated by any insertional mutagen. Here we present an optimized protocol for the amplification of splinkerette-PCR products, representing the junction between the MuLV viral U3LTR and a genomic insertion point. This protocol uses the restriction enzyme Sau3AI, and a compatible splinkerette adaptor, but can be adapted for any restriction enzyme and splinkeretteadaptor combination. The technique we describe is applicable to the isolation of insertion sites from transposons or other insertional mutagens with adaptation of the oligonucleotides used at each PCR step and the restriction enzymes used for cutting the genomic DNA. For simplicity this protocol is in single-tube format, but it can be scaled up to 96-well plate format. We have provided information on the equipment and reagents needed for performing this splinkerette method in 96-well plates throughout this protocol.
DNA extraction method. The quality of DNA used for splinkerette-PCR is critical. The DNA must be free of salt or other contaminants that may affect the PCR-amplification reactions. We have obtained good results using DNA extracted with Gentra Puregene kits (Qiagen). Although it is possible to perform splinkerette-PCR using DNA extracted by other methods, such as phenol-chloroform, we have found this to be less successful.
Choice of restriction enzyme. As splinkerette-PCR is a multiplex-PCR reaction, it will generally favor the amplification of shorter PCR products from within the pool of insertion sites found within a sample. The sequence of the genomic DNA between the viral LTR or transposon IR/DR is also likely to influence the recovery of an insertion, as GC-rich sequences may be harder to amplify. To obtain maximum coverage of insertion sites, it is preferable to use multiple restriction enzymes on each tumor DNA and several independent splinkerette reactions. For the isolation of retroviral insertion sites (from MuLV-induced tumors), we have had success using Sau3AI, Tsp509I and MspI although best results have been obtained with Sau3AI and MspI. Design of the splinkerette adaptor sequences. Although several splinkerette-adaptor sequences have been developed, the protocols described below use an adaptor sequence that was first reported by Mikkers et al. 17 .
Digestion of the adaptor-ligated splinkerette products. When the primary amplification primers are in a sequence that is repeated internally (e.g., the U3 LTR of MuLV) an appropriate restriction site must be found for digestion of the ligated DNA, to prevent the amplification of internal fragments. This site must be closer to the internal primer than the enzyme used to ligate the splinkerette to the DNA, i.e., digestion of the genomic DNA. In the case of isolating insertion sites from MuLV-induced tumor genomic DNA, it is necessary to digest the adaptor-ligated splinkerette genomic DNA to prevent the amplification of internal MuLV fragments from the internal U3-LTR sequence during the primary amplification PCR step. If Sau3AI, Tsp509I or MspI is used, then EcoRV is recommended for digestion of the adaptor-ligated splinkerette products, as the EcoRV site is closer to the internal LTR than these sites (Fig. 1a) .
Experimental controls. As with any PCR-based protocol it is important to always run a 'water only' negative control at each PCR step, to ensure that there is no systematic contamination of reagents. We also recommend including control DNA that does not contain insertion sites. The reason for this control is to ensure that non-specific amplification of sequence from endogenous 'psuedo-LTR' sequencing does not occur. An optimal result from splinkerette-PCR is a ladder of bands, as shown in Figure 1c .
Novice users of this protocol may wish to run a positive control that produces a known banding pattern on the agarose gel, which has been described in the expected results.
MATERIALS REAGENTS ! CAUTION When handling all the reagents described in this protocol wear gloves and suitable protective clothing, avoid contact with skin and eyes, and do not eat, drink or smoke. For further information for individual products, search at http://www.sigmaaldrich.com/technical-service-home/ product-catalog.html.
. Gentra Purgene Cell Kit (Qiagen, cat. no. 158767) ! CAUTION Some of the reagents used in this kit are classed as irritants. Gloves, lab coats and protective eyewear should be worn when using this kit.
. Ethanol . Ethidium bromide solution (10 mg ml À1 ) (Sigma-Aldrich, cat. no. E1510) ! CAUTION Ethidium bromide is a suspected mutagen and is a possible carcinogen. Gloves, lab coats, and protective eyewear should be worn when handling this reagent and any gels or solutions carrying it. Ethidium bromide-containing material should be disposed of in accordance with local institutional safety procedures.
. TOPO REAGENT SETUP Preparation of the splinkerette adaptor mix 'Long-strand adaptor' and 'short-strand adaptor' oligonucleotides (shown in Table 1 ) need to be purified by HPLC. The oligonucleotides should be resuspended in 5Â NEB buffer 2 (250 mM NaCl, 50 mM Tris-HCl, 50 mM MgCl 2 , 1 mM dithiothreitol; pH 7.9) to a concentration of 50 mM. Stocks can be frozen at À20 1C. Add 50 ml of 50 mM long-strand adaptor and 50 ml of 50 mM short-strand adaptor to a 1.5-ml tube and vortex to mix. Each adaptor primer will be present at a final concentration of 25 mM. This adaptor mix can be stored indefinitely at À20 1C and will provide enough splinkerette adaptors for 100 splinkerette-PCR reactions. SOC medium To 950 ml double-distilled water, add 20 g Bacto-tryptone, 5 g Bacto-yeast extract, 0.5 g NaCl and 2.5 ml of 1 M KCl. Adjust the pH to 7.0 with 10 N NaOH and then make up to a final volume of 1 liter using double-distilled water. Autoclave to sterilize, then store the medium at room temperature (21-25 1C). Add 20 ml sterile 1 M glucose immediately before use. SOC medium is stable for 1 week after the addition of the glucose. SOC medium with glucose provides a very rich environment for bacterial growth and can easily become contaminated even with good sterilization techniques. It is advisable to inspect the SOC medium for contamination, which will make the medium 'cloudy' , before use. LB+amp plates Add 10 g Bacto-tryptone, 5 g Bacto-yeast extract, 10 g NaCl and 15 g Bacto-agar to double-distilled water (such that the final volume is 1 liter). Autoclave to sterilize, cool to 55 1C, add 1 ml 100 mg ml À1 ampicillin (amp), then pour into sterile 10 cm 2 petri dishes. Store at 4 1C and dispose of unused plates after 3 weeks. LB+amp medium Add 10 g Bacto-tryptone, 5 g Bacto-yeast extract and 10 g NaCl to double-distilled water (such that the final volume is 1 liter). Autoclave to sterilize, then store at room temperature. To 1 liter add 1 ml 100 mg ml À1 ampicillin. After the addition of ampicillin store the medium for a maximum period of 2 weeks at 4 1C.
PROCEDURE
Tumor collection and storage 1| Collect mouse tumor material into screw-topped cryo-vials and snap-freeze in liquid nitrogen. The tissue can be stored at À80 1C (or in liquid nitrogen for long-term storage).
Extraction of tumor genomic DNA TIMING 4 h
2| Remove the cryo-vial from liquid nitrogen and place it on dry ice. With a sharp scalpel blade shave 5-10 mg of tissue from the tumor sample and extract the genomic DNA using the Gentra Purgene Cell Kit (Qiagen), according to the manufacturer's instructions. Unused tissue can be returned to the cryo-vial and stored in liquid nitrogen. ! CAUTION The solutions provided within the Gentra Puregene Cell Kit contain irritants such as proteinase K and lyticase. Gloves, lab coats and protective eyewear are recommended. Liquid nitrogen should be handled with care. ' PAUSE POINT The DNA can be stored at 4 1C or at À20 1C indefinitely.
Digestion of tumor genomic DNA with restriction enzyme TIMING 12-16 h 3| Digest the genomic DNA by setting up the reaction listed below, in a 1.5-ml tube. DNA quantities in the range of 0.5-5 mg are acceptable; 2 mg of DNA is optimal. We suggest quantifying DNA by spectrophotometry using a nanodrop. 4| Incubate the DNA digests at 37 1C overnight (12-16 h), either in a heating block or in an incubator. ' PAUSE POINT The digested genomic DNA can be stored at 4 1C or at À20 1C indefinitely.
Splinkerette adaptor ligation TIMING 12 h 5| Thaw the adaptor mix (prepared as described in 'reagent set up') on ice. Pipette the desired amount into a PCR tube (1 ml of adaptor mix per digested genomic DNA sample from Step 4). The adapter mix is then denatured and annealed by heating it to 95 1C for 5 min and then cooling to room temperature at the rate of 1 1C every 15 s. This is best carried out in a thermal cycler. Once completed the PCR tube should be kept on ice. 
7| Incubate the ligation reaction at 4 1C overnight (12-16 h).
8| Heat-inactivate the T4 DNA ligase at 65 1C for 20 min (in a heating block). ' PAUSE POINT The splinkerette ligation reaction can be stored at À20 1C indefinitely.
Digestion to remove genomic DNA fragments with splinkerette adaptor ligated on both ends TIMING 6 h 9| EcoRV digestion of the ligation reaction (from Step 8) removes any adaptor that has ligated onto the LTR end of the Sau3AI-digested genomic DNA (Fig. 1a) and prevents amplification of internal proviral fragments. Set up the following digestion reaction in a 1.5-ml tube:
per tube (ll) Final
Splinkerette adaptor ligation 40 -10Â NEB buffer 3 10 1Â EcoRV (20 U ml À1 ) 1 20 U Acetylated BSA (10 mg ml À1 ) 1 0.1 mg ml À1 Double-distilled water 48 -Final volume 100
10| Incubate the tube at 37 1C for at least 6 h (overnight is permitted).
11| Heat-inactivate the enzyme by heating the tube at 65 1C for 20 min (in a heating block).
' PAUSE POINT The EcoRV-digested splinkerette ligation reaction can be stored at À20 1C indefinitely.
Clean up the EcoRV digestion reaction TIMING 10 min 12| To clean up the splinkerette adaptor ligated DNA, use the QIAquick Gel Extraction Kit according to the manufacturer's instructions, with the exception that the DNA does not need to be run on an agarose gel. Simply add 600 ml of Buffer QG (supplied in the kit) to the reaction from Step 11 and complete the protocol as per the manufacturer's instructions. Elute the DNA in 40 ml of 10 mM Tris (pH 7.4). ! CAUTION Some of the solutions used with the QIAquick Gel Extraction Kit contain chaotropic salts that are irritants. Gloves, lab coats and protective eyewear are recommended.
13|
Although not always necessary, the samples can be quantified using a nanodrop (and are typically 5-15 ng ml À1 ). ' PAUSE POINT The purified splinkerette ligation reaction can be stored at À20 1C indefinitely.
Primary PCR amplification TIMING 2 h 14| To amplify the junction between the genome and the viral insertion, a nested-PCR reaction is used. Set up the primary PCR as follows, using the proofreading enzyme, Pfu. Primer sequences are shown in Table 1 . ' PAUSE POINT The primary PCR reaction can be stored at À20 1C indefinitely.
Secondary PCR amplification TIMING 2 h 16| Secondary PCR primers are nested relative to the primers used in the primary PCR and, therefore, increase the specificity of isolating virus/genome junctions. These primers may also be barcoded and tagged with the 454 'primer-A' and 'primer-B' sequences ( Table 1) . Set up the secondary PCR as follows:
per tube (ll) Final
Primary PCR product 1 -Splink2 primer (0.1 mg ml À1 )* 1 0.1 mg U3LTR#1 primer (0.1 mg ml À1 )* 1 0.1 mg Qiagen multiplex mastermix 25 -Double-distilled water 22 -Final volume 50 *Splink2-454 (A) and U3LTR#1-454 (B) must be used (see Table 1 ) if splinkerette PCR is to be sequenced on a 454 sequencer (see Step 19B). Agarose-gel analysis of splinkerette-PCR reactions TIMING 2 h 18| Visualize the results of the secondary splinkerette-PCR reaction by loading 15-20 ml on a 2%-4% agarose gel (in 1Â TAE) with ethidium bromide (0.5 mg ml À1 ). The PCR products should appear as a ladder (Fig. 1c) . The remaining PCR products should be purified using the QIAquick Gel Extraction Kit (as described in Step 12) . ! CAUTION Ethidium bromide is a known mutagen and a suspected carcinogen.
17|
? TROUBLESHOOTING
De-multiplexing and sequencing of splinkerette-PCR products 19| Splinkerette-PCR products now represent a pool that must be de-multiplexed before sequencing. This can be done either by shotgun cloning and capillary-read sequencing (option A) or by 454 sequence analysis (option B). 454 sequencing is only an option if the secondary PCR has been carried out using the Splink2-454 (A) primer and the U3LTR#1-454 (B) primer (Table 1) as the 'primer A' and 'primer B' sequences in these primers are essential for 454 sequencing. (ii) Incubate the reaction at 37 1C for 60 min, followed by 80 1C for 20 min.
(iii) Purify the PCR products using a Millipore filter plate. Add 20 ml of PCR product and 80 ml of HPLC water to the filter plate. Centrifuge the plate at 3,220g for 10 min at room temperature. Add 20 ml of HPLC water to the filter plate and centrifuge at 242g for 10 min at room temperature. Collect the re-suspended splinkerette-PCR products and place in a clean 96-well plate. ' PAUSE POINT The purified splinkerette-PCR can be stored at À80 1C indefinitely. (iv) Quantify the splinkerette-PCR products on a nanodrop and then pool the samples. We routinely pool 10-20 ml of PCR product from up to 100 splinkerette-PCR reactions (the DNA can be concentrated by ethanol precipitation to reduce the total final volume or using a Qiaquick column). m CRITICAL STEP The degree of multiplexing depends greatly on the application and the expected complexity of the pool, and it is probably best to optimize this factor for each experiment. We have designed primers so that in the second splinkerette-PCR primer B is incorporated into the splinkerette product at the LTR end and primer A is incorporated at the linker end. (v) Emulsion PCR should then be performed on these products using 'GS emPCR kit III' from Roche. A short nucleotide 'barcode' in the LTR end primer is used as a tag to computationally de-multiplex the 454 splinkerette-PCR sequences.
A list of suitable barcodes, designed to lack homopolymer stretches, is provided in Supplementary Table 1 online. m CRITICAL STEP The choice of barcodes should be carefully considered depending on the application. Five basepairs represents the minimum length of barcodes that should be used. Ten basepairs is optimal. To increase the unambiguous assignment of sequences to tumors within the pool of sequenced products, it may be desirable to use longer barcode sequences. Barcode length largely depends on the degree of multiplexing within each pool 20 . DNA-sequence trace analysis TIMING B 1 week 20| After the DNA sequences have been generated they need to be analyzed. The first phase of this process is to remove any contaminating sequences by identifying and discarding those sequence traces that do not contain the end of the LTR, or where the barcode cannot be read when sequencing was performed on the 454 platform. The software for mapping and analysis of insertion sites within the remaining sequences has been described elsewhere 14, [21] [22] [23] [24] .
TIMING
The entire splinkerette-PCR procedure usually takes 4-5 d depending on the duration of the digestion and ligation steps.
Step 2, Extraction of tumor genomic DNA: 4 h Steps 3-4, Digestion of tumor genomic DNA with Sau3AI: 12-16 h Steps 5-8, Splinkerette adaptor ligation: 12 h Steps 9-11, Digestion to remove genomic DNA fragments with splinkerette adaptor ligated on both ends: 6 h
Step 12, Clean-up of EcoRV digestion reaction: 10 min Steps 14 and 15, Primary PCR amplification: 2 h Steps 16 and 17, Secondary PCR amplification: 2 h
Step 18, Agarose-gel analysis: 2 h
Step 19A, Shotgun cloning before capillary read sequencing B 1 week
Step 19B, 454 'barcode' sequencing of splinkerette-PCR reactions B 1 day
Step 20, DNA-sequence trace analysis B 1 week
? TROUBLESHOOTING Troubleshooting advice can be found in Table 2 .
ANTICIPATED RESULTS
We have successfully used this approach to generate the DNA sequence of over 1,000 splinkerette-PCR reactions generated using both viruses and transposons. Successful splinkerette-PCR will yield a ladder of bands (Fig. 1c) . The number and size of the bands largely depend on the number of insertion sites in the tumor. When analyzing large numbers of tumors, it is important to perform several splinkerette-PCR reactions on control genomic DNA that does not contain any viral or transposon insertions. This is because there are elements such as pseudo-LTR or pseudo-transposon repeat-like sequences in every genome and these may be non-specifically amplified. Although rare, mis-priming of splinkerette primers can also yield PCR artifacts. Sequencing of a splinkerette-PCR product is the only sure way to ensure that it faithfully represents a true insertion site. Step Problem Solution 18
No splinkerette-PCR products on gel The splinkerette-PCR reaction has many steps and as such there are numerous places where the protocol may fail. The most frequent source of failure is an incorrect ratio of splinkerette-adaptor to genomic DNA in the splinkerette ligation. Be sure to carefully prepare the splinkerette adaptor and to quantify the genomic DNA before digestion 20 Chimeric splinkerette products One of the major contaminants in splinkerette-PCR is chimeric genomic sequences ligated between the LTR and the adaptor. These are splinkerettes carrying multiple genomic fragments between the end of the insertional mutagen and the linker. It is very difficult to remove these by modifying the splinkerette-PCR reaction, but these should be carefully masked out when the sequence data are analyzed Linker-genomic DNA-linker products Occasionally linker-genomic DNA-linker fragments are generated. The generation of these products is suppressed by cutting with an internal enzyme, or they can be masked out during the analysis of the sequence 
